SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Reports that Papa Johns largest U.S. franchisee joined Irth Capitals take-private bid have renewed buyout speculation. Traders are debating whether the board will accept a deal, against the backdrop of weak sales and previous rejected offers; no transaction is confirmed.

TOSHI

Renewed volume and choppy price action have traders watching for a breakout in TOSHI, with bullish posts anticipating a rally or short squeeze while skeptics point to repeated resistance and the risk of further lows. The discussion is largely speculative technical trading and community conviction around the Base meme coin, with no confirmed new catalyst dominating.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

New ESMO subgroup analyses from Celcuitys Phase 3 VIKTORIA-1 breast cancer study are drawing attention, with traders highlighting promising efficacy while noting the topline results were already known. The community is split on whether the update adds a fresh catalyst, with discussion also focused on the FDA review of the PIK3CA-mutant label expansion and the need to demonstrate commercial sales.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is drawing attention as crude oil rises amid Middle East tensions and fears of supply disruptions around the Strait of Hormuz. Bullish traders point to supply risks, while others warn that easing tensions or renewed diplomacy could trigger a pullback.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLEs breakout to fresh highs is drawing attention alongside rising crude prices and traders concerns about supply disruptions tied to the Iran conflict and Strait of Hormuz. Many see energy-sector strength and continued upside, while others warn the rally may be extended and vulnerable to reversals if geopolitical tensions ease.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Mercks partnered personalized mRNA melanoma vaccine with Moderna is drawing attention after Phase 3 results showed reduced recurrence or death risk when added to Keytruda. Traders are split between viewing the data as a meaningful oncology milestone with potential to support Keytruda and seeing it as a sell-the-news outcome that fell short of high expectations.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is drawing attention after a sharp third-quarter outlook cut tied to weak demand, excess distributor inventory, and price adjustments. Traders are split between viewing the reset and debt-reduction efforts as a path to recovery and fearing that persistent pressure on sales, margins, and debt could lead to restructuring or bankruptcy.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIB is drawing attention for choppy, largely sideways trading, with repeated technical posts describing consolidation and traders watching for a breakout. Optimistic holders are accumulating and anticipating a rebound, while skeptics point to the tokens lack of momentum and utility and expect further weakness.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

A sharply weaker quarterly report, reduced full-year outlook, and suspension of Whirlpools dividend have intensified concerns about weak appliance demand and the companys financial strain; management cited recession-level industry conditions and the Iran conflict. The community is largely bearish, criticizing management and raising debt and bankruptcy concerns, though some traders see the selloff as a buying opportunity.

Anthropic

Anthropics planned mega-IPO and reported financial disclosures are driving attention, with traders weighing rapid Claude revenue growth against heavy infrastructure commitments, losses, and an ambitious potential valuation. Bulls point to enterprise demand and pre-IPO exposure, while skeptics question the spending, competition, and sustainability of the business model.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet

The consensus price target hints at a 168.2% upside potential for Sagimet Biosciences Inc. (SGMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)

Sagimet Biosciences Inc. (SGMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise

Sagimet reports positive 52-week Phase 3 trial data for denifanstat in acne patients and prices a $115 million stock offering.read more...

Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial – SGMT Stock Surges Pre-Market

Equity

Sagimet’s Denifanstat produced a 57% treatment-success rate after up to 52 weeks.


Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion

Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion...

Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for Sagimet Biosciences Inc. (SGMT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade

The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 298.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?

Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?

The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 241.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Canaccord Genuity Group Raises Sagimet Biosciences (NASDAQ:SGMT) Price Target to $49.00

Canaccord Genuity Group raised their target price on Sagimet Biosciences from $28.00 to $49.00 and gave the stock a 'buy' rating in a research note on Monday...

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Bullish Sentiment

<ul class="summary-bullets"><li>Total acne lesions fell 72% and inflammatory lesions declined 77% in a Phase 3 extension study in China.</li><li>Its Phase 3 study in the U.S. is expected to enroll about 800 patients aged 12 and older.</li><li>Sagimet is raising $115 million at $10 per share, a 7% premium over Tuesday’s close.</li></ul>Shares of Sagimet Biosciences (<a class="mention" data-mention="$SGMT" data-symbol-id="SGMT" href="https://stocktwits.com/symbol/SGMT" target="_blank">SGMT</a>) rose 13% in pre-market trading on Wednesday after the biotech firm reported promising long-term results for its experimental acne drug and raised fresh capital to fund its upcoming U.S. Phase 3 trial.Sagimet’s Denifanstat produced a 57% treatment-success rate after up to 52 weeks, while total acne lesions fell 72% and inflammatory lesions declined 77% in a Phase 3 extension study in China conducted by Sagimet’s licensing partner, Ascletis.Denifanstat is a once-daily oral drug that blocks fatty acid synthase (FASN), an enzyme that causes acne. The drug was generally well tolerated, with no patients permanently stopping treatment because of adverse events.<h2 class="st-heading-2">U.S. Phase 3 Trial To Involve 800 Patients</h2>The results come as Sagimet prepares to begin screening patients in October for its Phase 3 study in the U.S. The trial is expected to enroll about 800 patients aged 12 and older, including roughly 450 adolescents.Patients will receive either Denifanstat or placebo for 12 weeks, with around 530 patients eligible to continue into a 40-week extension study. Sagimet said Denifanstat could potentially become the first oral acne treatment with a new mechanism of action approved in more than 40 years.<h2 class="st-heading-2">Sagimet Raises $115 Million To Fund Phase 3</h2>To fund its U.S. study, Sagimet announced that it is raising $115 million at $10 per share, along with pre-funded warrants. This represents a 7% premium over Tuesday’s close.Beyond funding the Phase 3 trial and a potential drug launch, the proceeds will also support TVB-3567, its other acne drug in development, through Phase 2 results and advance its topical FASN inhibitor program toward an Investigational New Drug (IND) application.Sagimet reported $257.6 million in cash, cash equivalents and marketable securities as of June 30, which the company expects would fund operations through 2028.<h2 class="st-heading-2">Retail’s Take On <a class="mention" data-mention="$SGMT" data-symbol-id="SGMT" href="https://stocktwits.com/symbol/SGMT" target="_blank">SGMT</a></h2>Retail sentiment surrounding&nbsp;<a href="https://stocktwits.com/symbol/SGMT">SGMT</a> on Stocktwits remained ‘extremely bullish’ over the past 24 hours amid ‘high’ message volumes. <a class="mention" data-mention="$SGMT" data-symbol-id="SGMT" href="https://stocktwits.com/symbol/SGMT" target="_blank">SGMT</a> was also among the top trending tickers at the time of writing.The stock has seen significant buying interest so far this year, gaining 56%.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/redwire-joins-growing-orbital-data-center-race-with-sophia-days-after-980-m-space-force-contract-selection/cZMFdJ7RBhh">&nbsp;Redwire Joins Growing Orbital Data Center Race With Sophia Days After $980M Space Force Contract Selection</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Sagimet’s Denifanstat produced a 57% treatment-success rate after up to 52 weeks.

Why Is SGMT Stock Surging Premarket Today?

Sagimet Biosciences Inc

SPDR S&P Biotech ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$9.58
Prev Close	$9.95
Open	$9.95
Dividend Yield	0.00%
50-Day Moving Average	$9.96
Beta	2.01
Avg. Volume	1.37M
PE Ratio	-7.48

52-Week High	$11.45
52-Week Low	$4.50
Market Capitalization	$673.87M
EPS (Annual)	-$1.58
Price to Book	2.31
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SGMT Fundamentals